Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free OGN Stock Alerts

Organon & Co. (OGN) Competitors

Organon & Co. logo
$13.76 +0.02 (+0.15%)
As of 08/21/2026 03:58 PM Eastern
Compare

OGN vs. CORT, ELAN, AXSM, RDY, and CRNX

Should you buy Organon & Co. stock or one of its competitors? Organon & Co.'s main competitors and comparable companies include Corcept Therapeutics (CORT), Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), Dr. Reddy's Laboratories (RDY), and Crinetics Pharmaceuticals (CRNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Organon & Co. compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Organon & Co. (NYSE:OGN) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

In the previous week, Corcept Therapeutics had 29 more articles in the media than Organon & Co.. MarketBeat recorded 31 mentions for Corcept Therapeutics and 2 mentions for Organon & Co.. Corcept Therapeutics' average media sentiment score of 0.79 beat Organon & Co.'s score of 0.14 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Corcept Therapeutics
11 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Organon & Co.
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Corcept Therapeutics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

Corcept Therapeutics presently has a consensus price target of $138.17, suggesting a potential upside of 13.02%. Organon & Co. has a consensus price target of $11.40, suggesting a potential downside of 17.15%. Given Corcept Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Corcept Therapeutics is more favorable than Organon & Co..

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corcept Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50
Organon & Co.
2 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.71

Organon & Co. has higher revenue and earnings than Corcept Therapeutics. Organon & Co. is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corcept Therapeutics$830.81M15.91$99.65M$0.42291.07
Organon & Co.$6.22B0.58$187M$0.7717.87

93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 20.7% of Corcept Therapeutics shares are held by company insiders. Comparatively, 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Corcept Therapeutics has a net margin of 6.52% compared to Organon & Co.'s net margin of 3.41%. Organon & Co.'s return on equity of 88.97% beat Corcept Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Corcept Therapeutics6.52% 8.26% 6.45%
Organon & Co. 3.41%88.97%6.03%

Summary

Corcept Therapeutics beats Organon & Co. on 11 of the 16 factors compared between the two stocks.

How does Organon & Co. compare to Elanco Animal Health?

Organon & Co. (NYSE:OGN) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Organon & Co. presently has a consensus target price of $11.40, indicating a potential downside of 17.15%. Elanco Animal Health has a consensus target price of $29.09, indicating a potential upside of 20.96%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, analysts clearly believe Elanco Animal Health is more favorable than Organon & Co..

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organon & Co.
2 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.71
Elanco Animal Health
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.77

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 1.6% of Organon & Co. shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Organon & Co. has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market.

Organon & Co. has a net margin of 3.41% compared to Elanco Animal Health's net margin of -3.96%. Organon & Co.'s return on equity of 88.97% beat Elanco Animal Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Organon & Co.3.41% 88.97% 6.03%
Elanco Animal Health -3.96%8.13%3.99%

Organon & Co. has higher revenue and earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organon & Co.$6.22B0.58$187M$0.7717.87
Elanco Animal Health$4.72B2.55-$232M-$0.41N/A

In the previous week, Elanco Animal Health had 14 more articles in the media than Organon & Co.. MarketBeat recorded 16 mentions for Elanco Animal Health and 2 mentions for Organon & Co.. Elanco Animal Health's average media sentiment score of 1.60 beat Organon & Co.'s score of 0.14 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Organon & Co.
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Elanco Animal Health
12 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Summary

Elanco Animal Health beats Organon & Co. on 9 of the 17 factors compared between the two stocks.

How does Organon & Co. compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Organon & Co. (NYSE:OGN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Comparatively, 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Axsome Therapeutics has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market.

Organon & Co. has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome Therapeutics$638.50M17.04-$183.17M-$3.75N/A
Organon & Co.$6.22B0.58$187M$0.7717.87

Organon & Co. has a net margin of 3.41% compared to Axsome Therapeutics' net margin of -24.68%. Organon & Co.'s return on equity of 88.97% beat Axsome Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Axsome Therapeutics-24.68% -265.55% -28.10%
Organon & Co. 3.41%88.97%6.03%

In the previous week, Axsome Therapeutics had 11 more articles in the media than Organon & Co.. MarketBeat recorded 13 mentions for Axsome Therapeutics and 2 mentions for Organon & Co.. Axsome Therapeutics' average media sentiment score of 1.53 beat Organon & Co.'s score of 0.14 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Axsome Therapeutics
11 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Organon & Co.
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Axsome Therapeutics currently has a consensus price target of $267.60, indicating a potential upside of 28.80%. Organon & Co. has a consensus price target of $11.40, indicating a potential downside of 17.15%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Axsome Therapeutics is more favorable than Organon & Co..

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Axsome Therapeutics
1 Sell rating(s)
3 Hold rating(s)
16 Buy rating(s)
2 Strong Buy rating(s)
2.86
Organon & Co.
2 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.71

Summary

Axsome Therapeutics beats Organon & Co. on 9 of the 17 factors compared between the two stocks.

How does Organon & Co. compare to Dr. Reddy's Laboratories?

Organon & Co. (NYSE:OGN) and Dr. Reddy's Laboratories (NYSE:RDY) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Organon & Co.'s net margin of 3.41%. Organon & Co.'s return on equity of 88.97% beat Dr. Reddy's Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Organon & Co.3.41% 88.97% 6.03%
Dr. Reddy's Laboratories 10.15%9.49%6.32%

In the previous week, Organon & Co. and Organon & Co. both had 2 articles in the media. Organon & Co.'s average media sentiment score of 0.14 beat Dr. Reddy's Laboratories' score of -0.73 indicating that Organon & Co. is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Organon & Co.
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Dr. Reddy's Laboratories
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Negative

Dr. Reddy's Laboratories has lower revenue, but higher earnings than Organon & Co.. Organon & Co. is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organon & Co.$6.22B0.58$187M$0.7717.87
Dr. Reddy's Laboratories$3.58B2.84$456M$0.4427.70

Organon & Co. presently has a consensus price target of $11.40, indicating a potential downside of 17.15%. Given Organon & Co.'s stronger consensus rating and higher probable upside, equities research analysts clearly believe Organon & Co. is more favorable than Dr. Reddy's Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organon & Co.
2 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.71
Dr. Reddy's Laboratories
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Organon & Co. has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

Organon & Co. pays an annual dividend of $0.08 per share and has a dividend yield of 0.6%. Dr. Reddy's Laboratories pays an annual dividend of $0.06 per share and has a dividend yield of 0.5%. Organon & Co. pays out 10.4% of its earnings in the form of a dividend. Dr. Reddy's Laboratories pays out 13.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Organon & Co. is clearly the better dividend stock, given its higher yield and lower payout ratio.

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Organon & Co. beats Dr. Reddy's Laboratories on 10 of the 16 factors compared between the two stocks.

How does Organon & Co. compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Organon & Co. (NYSE:OGN) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Organon & Co. has a net margin of 3.41% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Organon & Co.'s return on equity of 88.97% beat Crinetics Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Crinetics Pharmaceuticals-1,189.88% -44.22% -39.77%
Organon & Co. 3.41%88.97%6.03%

Crinetics Pharmaceuticals presently has a consensus target price of $81.00, suggesting a potential downside of 4.36%. Organon & Co. has a consensus target price of $11.40, suggesting a potential downside of 17.15%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than Organon & Co..

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Crinetics Pharmaceuticals
1 Sell rating(s)
11 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.24
Organon & Co.
2 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.71

In the previous week, Crinetics Pharmaceuticals had 2 more articles in the media than Organon & Co.. MarketBeat recorded 4 mentions for Crinetics Pharmaceuticals and 2 mentions for Organon & Co.. Crinetics Pharmaceuticals' average media sentiment score of 1.27 beat Organon & Co.'s score of 0.14 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Crinetics Pharmaceuticals
3 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Organon & Co.
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Crinetics Pharmaceuticals has a beta of 0.12, meaning that its stock price is 88% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market.

Organon & Co. has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crinetics Pharmaceuticals$7.70M1,166.63-$465.32M-$5.04N/A
Organon & Co.$6.22B0.58$187M$0.7717.87

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Crinetics Pharmaceuticals and Organon & Co. tied by winning 8 of the 16 factors compared between the two stocks.

Get Organon & Co. News Delivered to You Automatically

Sign up to receive the latest news and ratings for OGN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OGN vs. The Competition

Export
MetricOrganon & Co.Pharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$3.61B$12.57B$7.37B$24.30B
Dividend Yield0.58%2.61%2.53%3.70%
P/E Ratio17.87789.80272.6030.31
Price / Sales0.58764.53624.3319.95
Price / Cash2.3796.7778.6232.49
Price / Book3.5911.8913.056.77
Net Income$187M$2.81B$3.47B$1.07B
7 Day Performance0.33%1.77%2.09%-0.65%
1 Month Performance1.36%3.85%6.64%3.38%
1 Year Performance46.07%6.56%25.02%14.90%

Organon & Co. Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OGN
Organon & Co.
1.1729 of 5 stars		$13.76
+0.1%		$11.40
-17.2%		+46.1%$3.61B$6.22B17.8710,000
CORT
Corcept Therapeutics
3.4781 of 5 stars		$117.17
+2.4%		$119.17
+1.7%		+73.8%$12.37B$761.41M278.98300
ELAN
Elanco Animal Health
4.311 of 5 stars		$23.66
0.0%		$29.09
+23.0%		+34.4%$11.83B$4.72BN/A9,400
AXSM
Axsome Therapeutics
3.6746 of 5 stars		$216.27
+1.2%		$267.60
+23.7%		+75.3%$11.19B$776.57MN/A380
RDY
Dr. Reddy's Laboratories
1.8411 of 5 stars		$12.15
-1.0%		N/A-16.0%$10.24B$3.58B27.6127,527

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:OGN) was last updated on 8/23/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel